about
The role of genetic variation near interferon-kappa in systemic lupus erythematosusA large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosusVariable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestryManaging lupus patients during pregnancyUnmet medical needs in systemic lupus erythematosusEvidence-based management of thrombosis in the antiphospholipid antibody syndromeManagement of antiphospholipid syndrome in pregnancyThe relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort studyAspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individualsAnti-inflammatory and immunosuppressive drugs and reproductionA common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosusIRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosusA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusA functional haplotype of UBE2L3 confers risk for systemic lupus erythematosusAssociation of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAXGenetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four womenEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialAdmixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody productionThe SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAsFactors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception CohortEfficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyTime to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohortGenome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigreesDifferential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production.Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus.Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort.Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosusLongitudinal expression of type I interferon responsive genes in systemic lupus erythematosus.Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort.Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosusCyclophosphamide for lupus during pregnancy.Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?Early risk factors for pregnancy loss in lupus.Hydroxychloroquine in lupus pregnancy.
P50
Q21296846-73992DA4-7C75-4FEB-ADDC-3B6725150931Q24629130-62C51750-1ABE-4962-A8F2-F77EAAEDD51BQ24633276-347E9C16-EE22-4144-BD66-D9B71380D205Q27002228-DBBC211A-232A-499E-8EA5-55602DBB4767Q27005906-7E0DBEB8-5374-4CE3-B857-8F9B078C2361Q28165262-E4D41944-D793-46A3-9496-42E1A7D8843AQ28199914-A7F558B8-6125-48C9-9A73-57F95E3CB37EQ28212163-7D674CAC-1985-449C-BEAB-A717B073DCEDQ28217805-D75C4AB9-4B5C-421F-89ED-157309FAE6E4Q28218219-5A428527-FC7C-463D-A9A0-3EC788295E8FQ28236839-27A97EC7-2D74-469D-8B24-8EF80B86412EQ28253129-AACD6B83-9B4A-4FDC-A458-00BAF66E3FFEQ28254310-F7AC58C1-439C-4878-954F-905B5BCDBD91Q28263690-715C5F33-EC14-41E6-A05C-F6B648CF4266Q28265206-338C82EF-79FB-450F-8455-EF4E3355FF09Q28273794-36BD49D5-44BB-475E-BF0A-61AAE72A4AD6Q28290612-6157FD07-8C46-4D08-B965-D73116EB0F51Q28304807-0E5AC48C-D0BF-4ED3-9CC2-A3F5CEE840E1Q28486228-42719103-9210-45BE-AB6E-5C485A2B8198Q28538471-94E5CD44-7A3B-4339-8C22-F6444908C4C0Q28608340-3D9F064C-70A3-440E-9D77-584CDE7A6444Q28660706-9FC2E507-242C-4A70-8E3F-F2F221B914D2Q28766942-2D7AFF6D-EC43-4C93-BE5D-CBC5E845D1A4Q28776419-A88463A5-7D60-49E8-B5E1-D1E17CF122A3Q29417056-50B293BC-219F-4FF0-9F5F-B2BBE6A66BF3Q30409882-0D2F1227-17DD-404B-835C-BBCC2782AB95Q30560952-CEFF5C51-67DB-4CD2-89BE-FE672022DD7DQ30580226-91CF971D-80D8-4820-87A7-F3F83D270145Q30645037-715BBDC1-E50C-48AE-AA9C-8A4BF7601EC3Q30791606-97613CE5-E58B-4CCC-A7F8-AED8089BDA22Q30823425-50CEA3AC-8ECD-44F5-92EC-5F32CDB14829Q30828464-86E3FF70-E256-466C-9F68-3BF84E65E0E4Q30873883-9DE565B9-AE30-4004-994C-5A814EA8FDCBQ31122937-28197B56-F8B0-4E99-9ACF-A637590D2250Q31145074-06455FC4-3369-4A86-9C5A-3F65C666B659Q33339386-AFF09897-8032-4674-B7BF-4F00CF9A0D9FQ33368551-1C16E6FD-9DFA-46F9-A6EE-67934D9B6F03Q33369397-ED822EBD-8C4A-4FEE-881D-A0F9DBCC00D1Q33370141-CAE04675-5A01-4998-88D4-471F126577F8Q33373145-ECA67AF6-F349-4DDB-92B3-E41D60AE64FA
P50
description
forsker
@nb
researcher
@en
name
Michelle A. Petri
@en
Michelle A. Petri
@nl
Michelle Petri
@da
Michelle Petri
@de
Michelle Petri
@fr
Michelle Petri
@nb
Michelle Petri
@nn
Michelle Petri
@sv
Petri M
@ast
Petri M
@es
type
label
Michelle A. Petri
@en
Michelle A. Petri
@nl
Michelle Petri
@da
Michelle Petri
@de
Michelle Petri
@fr
Michelle Petri
@nb
Michelle Petri
@nn
Michelle Petri
@sv
Petri M
@ast
Petri M
@es
altLabel
Michelle Petri
@en
Petri M
@en
prefLabel
Michelle A. Petri
@en
Michelle A. Petri
@nl
Michelle Petri
@da
Michelle Petri
@de
Michelle Petri
@fr
Michelle Petri
@nb
Michelle Petri
@nn
Michelle Petri
@sv
Petri M
@ast
Petri M
@es